pronostiques, améliorant ainsi notre système pronostique existant, de sorte
que les patients à haut risque, en particulier ceux qui sont actuellement cachés
au sein des groupes à faible risque, puissent être identifiés dès que possible,
afin de permettre l'augmentation de la thérapie.
Références
1. Allis CD, Reinberg D, Jenuwein T (2007) Epigenetics. Cold Spring Harbor
Laboratory Press
2. Amaar YG, Tapia B, Chen ST, Baylink DJ, Mohan S (2006) Identification and
characterization of novel IGFBP5 interacting protein: evidence IGFBP5-IP is a
potential regulator of osteoblast cell proliferation. Am J Physiol Cell Physiol
290: C900-6
3. Aprelikova O, Pandolfi S, Tackett S, Ferreira M, Salnikow K, Ward Y, Risinger
JI, Barrett JC, Niederhuber J (2009) Melanoma antigen-11 inhibits the
hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.
Cancer Res 69: 616-24
4. Armstrong SA, Look AT (2005) Molecular genetics of acute lymphoblastic
leukemia. J Clin Oncol 23: 6306-15
5. Aspland SE, Bendall HH, Murre C (2001) The role of E2A-PBX1 in
leukemogenesis. Oncogene 20: 5708-17
6. Ayton PM, Cleary ML (2001) Molecular mechanisms of leukemogenesis
mediated by MLL fusion proteins. Oncogene 20: 5695-707
7. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A,
Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H,
Klingebiel T, von Stackelberg A (2009) Prognostic value of minimal residual
disease quantification before allogeneic stem-cell transplantation in relapsed
childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J
Clin Oncol 27: 377-84
8. Bai S, Wilson EM (2008) Epidermal-growth-factor-dependent phosphorylation
and ubiquitinylation of MAGE-11 regulates its interaction with the androgen
receptor. Mol Cell Biol 28: 1947-63
9. Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C,
Stary J, Felice MS, Magyarosy E, Conter V, Reiter A, Messina C, Gadner H,
Schrappe M (2005) Chemotherapy versus allogeneic transplantation for
very-high-risk childhood acute lymphoblastic leukaemia in first complete
remission: comparison by genetic randomisation in an international
prospective study. Lancet 366: 635-42
10. Bassan R, Hoelzer D (2011) Modern therapy of acute lymphoblastic leukemia.
J Clin Oncol 29: 532-43
11. Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D,
Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A,
Gaipa G (2009) Risk of relapse of childhood acute lymphoblastic leukemia is
predicted by flow cytometric measurement of residual disease on day 15 bone
marrow. J Clin Oncol 27: 5168-74
12. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg
RA (2008) An embryonic stem cell-like gene expression signature in poorly
differentiated aggressive human tumors. Nat Genet 40: 499-507
cellular identity goes awry. Dev Cell 19: 698-711
14. Bhatia S, Landier W, Shangguan M, Hageman L, Schaible AN, Carter AR,
Hanby CL, Leisenring W, Yasui Y, Kornegay NM, Mascarenhas L, Ritchey AK,
Casillas JN, Dickens DS, Meza J, Carroll WL, Relling MV, Wong FL (2012)
Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and
non-Hispanic white children with acute lymphoblastic leukemia: a report from
the children's oncology group. J Clin Oncol 30: 2094-101
15. Bhojwani D, Kang H, Menezes RX, Yang W, Sather H, Moskowitz NP, Min DJ,
Potter JW, Harvey R, Hunger SP, Seibel N, Raetz EA, Pieters R, Horstmann
MA, Relling MV, den Boer ML, Willman CL, Carroll WL (2008) Gene
expression signatures predictive of early response and outcome in high-risk
childhood acute lymphoblastic leukemia: A Children's Oncology Group Study
[corrected]. J Clin Oncol 26: 4376-84
16. Bornkamm GW (2009) Epstein-Barr virus and the pathogenesis of Burkitt's
lymphoma: more questions than answers. Int J Cancer 124: 1745-55
17. Borowitz M, Chan J (2008) T leucémie lymphoblastique / lymphome. .
Classification OMS des tumeurs des tissus hématopoïétiques et lymphoïdes,
4th edn. IARC, Lyon, pp 176-178
18. Bouhallier F, Allioli N, Lavial F, Chalmel F, Perrard M-H, Durand P, Samarut J,
Pain B, Rouault J-P (2010) Role of miR-34c microRNA in the late steps of
spermatogenesis. RNA 16: 720-31
19. Boussouar F, Jamshidikia M, Morozumi Y, Rousseaux S, Khochbin S (2013)
Malignant genome reprogramming by ATAD2. Biochim Biophys Acta in press
20. Boussouar F, Rousseaux S, Khochbin S (2008) A new insight into male
genome reprogramming by histone variants and histone code. Cell Cycle 7:
3499-502
21. Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, Barbry P,
Debernardi A, Brambilla C, Brambilla E, Rousseaux S, Khochbin S (2010)
Functional characterization of ATAD2 as a new cancer/testis factor and a
predictor of poor prognosis in breast and lung cancers. Oncogene 29: 5171-81
22. Carroll WL (2013) Safety in numbers: hyperdiploidy and prognosis. Blood 121:
2374-6
23. Carroll WL, Raetz EA (2012) Clinical and laboratory biology of childhood acute
lymphoblastic leukemia. J Pediatr 160: 10-8
24. Chen B, Wang YY, Shen Y, Zhang WN, He HY, Zhu YM, Chen HM, Gu CH,
Fan X, Chen JM, Cao Q, Yang G, Jiang CL, Weng XQ, Zhang XX, Xiong SM,
Shen ZX, Jiang H, Gu LJ, Chen Z, Mi JQ, Chen SJ (2012) Newly diagnosed
acute lymphoblastic leukemia in China (I): abnormal genetic patterns in 1346
childhood and adult cases and their comparison with the reports from Western
countries. Leukemia 26: 1608-16
25. Ciró M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, Nucifero
P, Pacchiana G, Capra M, Christensen J, Helin K (2009) ATAD2 is a novel
cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer
Res 69: 8491-8
26. Copelan EA, McGuire EA (1995) The biology and treatment of acute
lymphoblastic leukemia in adults. Blood 85: 1151-68
27. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S,
Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ,
Deininger MW, Talpaz M (2012) Ponatinib in refractory Philadelphia
chromosome-positive leukemias. N Engl J Med 367: 2075-88
28. Dixon JR, Selvaraj S, Yue F, Kim A, Li Y, Shen Y, Hu M, Liu JS, Ren B (2012)
Topological domains in mammalian genomes identified by analysis of
chromatin interactions. Nature 485: 376-80
29. Downing JR (2003) The core-binding factor leukemias: lessons learned from
murine models. Curr Opin Genet Dev 13: 48-54
30. Doyle JM, Gao J, Wang J, Yang M, Potts PR (2010) MAGE-RING protein
complexes comprise a family of E3 ubiquitin ligases. Mol Cell 39: 963-74
31. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM,
Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL
Dans le document
Evaluation du potentiel clinique de l'expression ectopique de gènes dans les Leucémies Lymphoblastiques Aigues
(Page 114-117)